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Surveillance of antimicrobial use in a Turkish university hospital
Rabin SABA, Dilara İNAN, Özge TURHAN, Ata Nevzat YALÇIN, Filiz GÜNSEREN, Latife MAMIKOĞLU

Aim: To determine antimicrobial use in a university hospital in Turkey and compare it with United States antimicrobial
use and resistance (US-AUR) and International Nosocomial Infection Control Consortium (INICC) rates.
Materials and methods: This was a prospective surveillance study done between January 2007 and December 2007. The
data are standardized by use of the defined daily dose (DDD) for each antimicrobial group and by calculating use per
1000 patients (antibiotic use density-AD).
Results: Data on 35,936 patients with a total of 215,616 patient-days were analyzed. Ampicillin group (mainly with a
beta lactamase inhibitor) has the highest AD in ICU and non-ICU departments (AD was 308 and 244 DDD/1000 patient
day, respectively). Compared with the US-AUR rates ADs for ampicillin group, antipseudomonal penicillin group, 1st
generation cephalosporins and carbapenems were over the 75th percentile for almost all types of ICU. Fluoroquinolones
AD was below the 10th percentile at most ICUs. Inversely compared with INICC data, none of antimicrobial group
exceeded the 90th percentile for all ICUs. There was a statistically significant (P < 0.01) correlation between incidence
densities of all nosocomial infections and ventilator utilization rate with the use of antipseudomonal penicillins, 3rd
generation cephalosporins, carbapenems, and glycopeptides at ICUs.
Conclusion: We found a positive correlation with nosocomial infections densities and the use of broad spectrum
antimicrobials in ICUs. To use antimicrobials wisely we must implement a comprehensive education program together
with infection control measures. A national program for antimicrobial usage may provide more precise data for interhospital comparisons.
Key words: Antibiotic surveillance, daily defined dose

Bir üniversite hastanesinde antibiyotik kullanımı surveyansı
Amaç: Türkiye’de bir üniversite hastanesinde antibiyotik kullanımı surveyansını yapmak ve sonuçları Amerika Birleşik
Devletleri antimikrobiyal kullanımı ve direnç programı (US- AUR) ve International Nosocomial Infection Control
Consortium (INICC) verileri ile karşılaştırmak.
Yöntem ve gereç: Bu prospektif bir surveyans çalışmasıdır. Ocak 2007- Aralık 2007 tarihleri arasında yatarak tedavi
gören hastalar çalışmaya dahil edilmiştir. Veriler her antibiyotik grubu için günlük tanımlanmış doz (DDD) kullanılarak
standardize edilmiş ve antibiyotik kullanım densitesini (AD) hesaplamak amacıyla 1000 hasta gününe çevrilmiştir.
Bulgular: Yatarak tedavi gören 35936 hastanın toplam 215616 hasta gününün verileri analiz edilmiştir. Yoğun
bakım ünitelerinde (YBÜ) ve YBÜ dışında kalan servislerde ampisilin grubu antibiyotikler en yüksek AD’ne sahipti
(sırasıyla 308 ve 244 DDD/1000 hasta günü). ABD verileri ile karşılaştırıldığında ampisilin, 1. kuşak sefalosporin,
antipsödomonal penisilin, ve karbapenem grubu antibiyotiklerin AD’si hemen hemen tüm YBÜ’i için 75. pörsantilin
üzerindeydi. Florokinolon AD ise çoğunda 10. pörsantilin altındaydı. Zıt olarak INICC verileriyle karşılaştırıldığında
tüm YBÜ’de hiçbir antibiyotik grubu 90. pörsantilin üzerinde değildi. YBÜ’deki tüm hastane infeksiyonları ve ventilator
kullanım oranları ile antipsödomonal penisilin, 3. kuşak sefalosporin, karbapenem ve glikopeptid AD’leri arasında
pozitif korelasyon mevcuttu (P < 0,01).
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Sonuç: YBÜ’de hastane infeksiyon densiteleri ve geniş spektrumlu antibiyotik kullanımı arasında pozitif bir korelasyon
mevcuttu. Bu yüzden antibiyotikleri akılcı kullanmak amacıyla infeksiyon kontrol önlemleri ile beraber kapsamlı bir
eğitim programı uygulanmalıdır. Hastaneler arasında karşılaştırma yapabilmek için antibiyotik kullanımının ulusal bir
program çerçevesinde takip edilmesinin yarar sağlayacağı düşünülmüştür.
Anahtar sözcükler: Antibiyotik, surveyans, tanımlanmış günlük doz

Materyal and Methods

Introduction
Mortality from infectious disease has decreased
over the last decades with the use of antimicrobials
but the early prediction of the approaching end of all
bacterial infections has never come true (1). Many
organisms have developed resistance to antimicrobials
to which they used to be susceptible. Nowadays the
major concern about the nosocomial infections in
the hospital setting is antimicrobial resistance (2,3).
The emergence of resistance is multifactor and the
relationship between antimicrobial uses is complex.
The World Health Organization (WHO) and the
European Commission pointed out the importance
of antimicrobial consumption (4,5). It is necessary
to detect resistance pathogens but it is also necessary
to monitor antimicrobial usage. Surveillance of
antimicrobial use is not enough; comparison of the data
is also essential. Surveillance data regarding antibiotic
use in hospitals in Turkey are absent. In the USA, the
National Nosocomial Infections Surveillance (NNIS)
System (formerly the National Healthcare Safety
Network (NHSN)) antimicrobial use and resistance
(AUR) and globally International Nosocomial
Infection Control Consortium (INICC) are providing
information on the use of antimicrobials (2,3,6).
The present study reports the results on the
surveillance of antimicrobial use in our hospital,
which is the first of its kind in Turkey, and compares
them with those in NNIS and INICC reports.

Study population
The study was conducted in the Akdeniz
University hospital, which is the referral hospital in
Antalya, Turkey, with 741 clinical and intensive care
unit (ICU) beds. Data were collected and analyzed
from January 2007 to the end of December 2007.
Surveillance of antimicrobial use was done in all
hospital and nosocomial infection surveillance was
carried out in 6 adult medical and surgical ICUs with
a total of 53 ICU beds (2 medical-surgical ICUs with
8 and 16 beds and cardiovascular (CV) ICU with 11
beds, thoracic ICU with 7 beds, coronary care unit
with 7 beds, and medical ICU with 4 beds).
Pharmacy data
Data on annual consumption of antimicrobials
were obtained from the Pharmacy of the hospital
with the help of data processing center. Grams of
antimicrobial agents were converted into numbers
of defined daily doses used in the defined period.
Antimicrobial agents with similar spectrum or
clinical indications were grouped as shown in Table 1.
A defined daily dose is the average daily dose in grams
of a specific antimicrobial agent given to an average
adult patient (Table 1) (2). Then we determined the
antimicrobial use density (AD), expressed as DDD
per 1000 patient days for each antimicrobial group.

total antibiotic use in grams in the defined period
AD =

×
defined daily dose

Surveillance data on nosocomial infections
Infection control nurses and an infection control
practitioner visited the ICUs 3 times per week and
nosocomial infections were defined according to
Centers for Disease Control and Prevention criteria
702

1000
patients days in the defined period

(7). Nosocomial infections were considered to be
ICU associated if they developed in the ICU or within
48 h of discharge from the ICU and if there was no
evidence that the infection was present or incubating
at the time of admission to the ICU. To calculate
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Table 1. Defined daily dose (DDD) of antimicrobial agents and their groups.
Group

Antimicrobial agent

DDD*

Penicillin group

Penicillin G
Procaine Penicillin G
Penicillin G benzathine
Penicillin V

Ampicillin group

Ampicillin (parenteral)
Ampicillin (oral)
Ampicillin/sulbactam
Amoxicillin (oral)
Amoxicillin/Clavulanic Acid (oral)

2g
2g
2g
1g
1g

Antipseudomonal penicillin

Piperacillin
Piperacillin/Tazobactam

14 g
14 g

1st generation cephalosporins

Cefazolin
Cefadroxil (oral)
Cephalexin (oral)

3g
2g
2g

2nd generation cephalosporins

Cefoxitin
Cefuroxime
Cefuroxime axetil (oral)
Cefaclor (oral)
Cefprozil (oral)

6g
3g
1g
1g
1g

3rd generation cephalosporins

Cefotaxime
Ceftazidime
Ceftizoxime
Ceftriaxone
Cephoperazone/sulbactam
Cefixime (oral)

Carbapenem group

Meropenem
Imipenem cilastatin

Fluoroquinolones

Ciprofloxacin (parenteral)
Ciprofloxacin (oral)
Ofloxacin (parenteral)
Ofloxacin (oral)
Levofloxacin (parenteral)
Levofloxacin (oral)
Moxifloxacin (parenteral)
Moxifloxacin (oral)

0.5 g
1g
0.4 g
0.4 g
0.5 g
0.5 g
0.4 g
0.4 g

Trimetophrim/sulfamethoxazole

Trimethoprim component (oral)
Trimethoprim compound (parenteral)

0.4 g
0.4 g

Glycopeptides

Vancomycin (parenteral)
Teicoplanin

2g
0.4 g

1.2 × 106 U
2.4 × 106 U
1.2 ×106 U
1g

4g
4g
4g
2g
4g
0.4 g
2g
2g

*DDD = daily defined dose
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nosocomial infection rates, the number of patients
in the ICU, the total number of patient-days, urinary
catheter-days, ventilator-days, and central line-days
were collected each month. The overall nosocomial
infection rates per patient and per patient-day
were calculated by dividing the total number of
nosocomial ICU infections by the total number
of ICU patients (×100) and patient-days (×1000),
respectively. For pneumonia, blood stream infection
(BSI), and urinary tract infection (UTI), each deviceassociated infection rate was calculated by dividing
the total number of device-associated infections by
the total number of device-days and then multiplying
the result by 1000. Device utilization ratios for
ventilators, central lines, and urinary catheters were
calculated by dividing the total number of devicedays by the total number patient-days.
Statistical methods
The pharmacy data were collected by using the
Medi-ecz program, which was written by our data
proceeding center. Nosocomial infections data were
abstracted from standard form and analyzed using
Epi-info software (version 6.04b: CDC). Correlation
coefficients between antimicrobial use density
with device associated infection rates and device
utilization rates were calculated by using SPSS 10.0
(Statistical Package for the Social Sciences).

percentile at any ICU and fluoroquinolones AD was
even below the 10th percentile at most ICUs (Table 2).
The highest AD was observed in the ampicillin group
(mainly with beta lactamase inhibitors), followed by
1st generation cephalosporins in all ICUs. For all ICUs
compared with INICC report ADs were between the
25th and 90th percentiles except for quinolones, which
was below the 25th percentile (Table 3). The most
commonly used antibiotic group was the ampicillin
group, with AD of 244 at non-ICU departments.
Quinolones and TMP/STZ ADs were over the 90th
percentile according to the INICC report but at
most the 25th percentile according to the NNISS
report. Inversely carbapenems AD was over the 90th
percentile according to the NNISS report whereas it
was only the 25th percentile according to the INICC
report (Table 4).
Device utilization ratios and incidence densities
for specific device associated infections in all types of
ICUs and their correlations with the ADs are shown
in Tables 5 and 6. There were positive correlations
between incidence densities of all nosocomial
infections and ventilator utilization rate with the
use of antipseudomonal penicillins, 3rd generation
cephalosporins, carbapenems, and glycopeptides at
ICUs (P < 0.01).
Discussion

Results
In 2007, 35,936 patients were hospitalized with a
total of 215,616 patient-days. Antimicrobial use was
analyzed as all ICUs and also according to the type of
ICUs in order to compare the results with those in NNIS
and INICC reports. The ampicillin group (mainly
with beta lactamase inhibitor) was the antimicrobial
with the highest AD in all ICUs except CV ICU,
where first generation cephalosporins had the highest
AD. Ampicillin group antibiotics AD were over the
90th percentile at cardiovascular, thoracic, medical,
and coronary ICUs according to the NNISS report.
Antipseudomonal penicillin (piperacillin) AD was
over the 90th percentile except the coronary unit. First
generation cephalosporins’ percentile was over 90 at
cardiovascular and thoracic ICUs. Carbapenem group
antibiotics AD were over the 90th percentile except
thoracic ICU. Fluoroquinolones and trimetophrim/
sulfamethoxazole ADs were not exceeding the 90th
704

The present study provides the first detailed
information of its kind on antimicrobial use
in a Turkish hospital. Although there are some
multicenter studies on antibiotic consumption in
Mediterranean hospitals, which included some
Turkish hospitals, their data do not contain hospital
data separately (8,9). The ampicillin group (mainly
with a beta lactamase inhibitor) has the highest ADs
in all ICUs (except cardiovascular ICU). In Turkey
there is no antistaphylococcal penicillin on the
market. Therefore, penicillin with a beta lactamase
inhibitor instead of antistaphylococcal penicillin is
used. Nevertheless, penicillins with a beta lactamase
inhibitor were the antimicrobial group with the
highest ADs in most reports including INICC
and SARI (surveillance of antimicrobial use and
antimicrobial resistance in intensive care units)
(3,10). According to US-AUR data the most widely
used antibiotic group was also ampicillin group except
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Table 2. Antimicrobial used density according to the type of ICUs and their percentiles
according to US-AUR report.
Antimicrobial group

AD*

US-AUR percentile

Penicillin group
MS ICU 1+

9

MS ICU 2

-

CV ICU§

-

Thoracic ICU

-

¶

M ICU

-

Coronary unit

-

25-50

Ampicillin group
MS ICU 1

285

50-75

MS ICU 2

301

75-90

CV ICU

382

>90

Thoracic ICU

982

>90

M ICU

389

>90

Coronary unit

299

>90

MS ICU

145

>90

MS ICU

141

>90

CV ICU

51

>90

Thoracic ICU

50

>90

+

Antipseudomonal penicillin

+

M ICU

120

>90

51

75-90

MS ICU 1

186

75-90

MS ICU 2

167

75-90

CV ICU

493

>90

Thoracic ICU

591

>90

M ICU

46

75-90

Coronary unit

13

10-25

2nd generation cephalosporins
MS ICU 1
MS ICU 2
CV ICU+
Thoracic ICU
M ICU
Coronary unit

1
-

Coronary unit
1st generation cephalosporins

+

<10
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Table 2. (Continued).
Antimicrobial group

AD*

US-AUR percentile

MS ICU 1

292

>90

MS ICU 2

177

75-90

CV ICU+

50

25-50

3rd generation cephalosporins

Thoracic ICU

57

25-50

145

50-75

26

10-25

MS ICU 1

180

>90

MS ICU 2

110

>90

M ICU
Coronary unit
Carbapenem group

+

CV ICU

57

>90

Thoracic ICU

35

25-50

130

>90

33

>90

MS ICU 1

19

<10

MS ICU 2

10

<10

CV ICU+

8

10-25

Thoracic ICU

18

25-50

M ICU

45

<10

Coronary unit

29

<10

MS ICU 1

62

50-75

MS ICU 2

34

50-75

CV ICU

17

50-75

Thoracic ICU

14

50-75

M ICU

10

75-90

MS ICU 1

248

>90

MS ICU 2

153

>90

CV ICU+

61

25-50

M ICU
Coronary unit
Fluoroquinolones

Trimetophrim/sulfamethoxazole

+

Coronary unit
Glycopeptides

Thoracic ICU
M ICU
Coronary unit

50

25-50

172

25-50

24

25-50

*AD = antimicrobial used density +MS ICU = medical surgical intensive care unit
§
CV ICU = cardiovascular intensive care unit ¶M ICU = medical intensive care unit
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Table 3. Antimicrobial used density in all ICUs and its percentile according to INICC.
AD*

INICC percentile

Penicillin group

1

50

Ampicillin group

308

75-90

Antipseudomonal penicillin

76

50-75

1st generation cephalosporins

190

75-90

2nd generation cephalosporins

0.13

25-50

3rd generation cephalosporins

101

25-50

Carbapenem group

70

25-50

Fluoroquinolones

13

<25

Trimetophrim/sulfamethoxazole

26

75-90

Glycopeptides

93

50-75

Antimicrobial group

*

AD = antimicrobial used density

Table 4. Antimicrobial used density in non- ICUs and their percentiles according to NNIS and
INICC.
AD*

INICC percentile

US-AUR percentile

Penicillin group

14

75-90

10-25

Ampicillin group

244

50-75

75-90

Antipseudomonal penicillin

27

75-90

50-75

1st generation cephalosporins

108

>90

75-90

2nd generation cephalosporins

9

75-90

<10

3rd generation cephalosporins

67

25-50

50-75

Carbapenem group

31

25

>90

Fluoroquinolones

36

>90

<10

Trimetophrim/sulfamethoxazole

11

>90

10-25

Glycopeptides

20

25-50

25-50

Antimicrobial group

*

AD = antimicrobial used density
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Table 5. Device utilization ratios and incidence densities for specific device associated infections in ICUs.
MS ICU*

MS ICU2

CV ICU+

Thoracic ICU

M ICU

Coronary

8

16

11

7

4

7

46.33

33.32

7.08

11.35

21

7.84

0.6

0.55

0.16

0.24

0.51

0.16

33.41

16.22

10.14

21.22

14.22

17.14

CVC¶ utilization rate

0.88

0.83

0.56

0.36

0.64

0.14

CVC associated BSI**

2.16

1.06

0.6

0.98

0.94

0.82

0.56

0.90

0.44

6.62

7.15

1.23

2.34

2.41

6.56

Number of beds
Incidence density of NI
Ventilator utilization rate
VAP

§

Urinary catheter utilization rate
++

Urinary catheter associated UTI

*MS ICU = medical surgical intensive care unit;
CV ICU = cardiovascular intensive care unit;
§
VAP = ventilator associated pneumonia;
+

3.4

¶

CVC = central venous catheter
**BSI = blood stream infection
++
UTI = urinary tract infection

Table 6. Correlation coefficients between antimicrobial use densities with device associated infection rates and device utilization rates
at ICUs.
Antimicrobial use density
Ampicillin
group

Antipseu+

1st
generation

3rd
generation

Carbapenem

Quinolon

TMP

Glycopeptide

Number of beds

-0.251

-0.091

-0.065

-0.064

-0.139

-0.416

0.132

-0.109

Incidence density
of all NI

-0.370

0.922*

-0.323

0.933*

0.907*

-0.065

0.806

0.929*

Ventilator
utilization rate

-0.350

0.968*

-0.427

0.918*

0.908*

0.152

0.722

0.935*

VAP§

0.021

0.428

-0.076

0.612

0.541

-0.049

0.750

0.571

CVC¶ utilization
rate

-0.376

0.849

-0.09

0.859

0.845

-0.242

0.829

0.867

CVC associated
BSI++

-0.532

-0.011

-0.544

0.058

-0.006

0.005

-0.101

-0.058

Urinary catheter
utilization rate

-0.446

0.813

-0.138

0.792

0.841

-0.129

0.716

0.847

Urinary catheter
associated UTI§§

-0.527

0.493

-0.619

0.459

0.323

-0.120

0.446

0.325

*Correlation is significant at a level of 0.01 +Antipseu = antipseudomonal §VAP = ventilator associated pneumonia
CVC= central venous catheter ++BSI = blood stream infection §§UTI = urinary tract infection

¶

cardiothoracic and medical ICUs (2). The highest
AD (982) for the ampicillin group was at the thoracic
ICU. Thoracic surgeons use ampicillin–sulbactam for
every patient in whom thoracic tube was employed
708

until the patient was discharged. In the cardiovascular
ICU the highest AD belongs to 1st generation
cephalosporins, which are the primary choice for
surgical prophylaxis. Evaluating and analyzing these
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results, we recognized that cardiovascular surgeons
are giving prophylaxis until all catheters are removed.
Education programs and seminars were organized in
order to apply good surgical prophylaxis. In addition
a surgical prophylaxis guideline was prepared.
Inappropriate use of antimicrobials has economic
and ecological implications for society (11,12).
Hospitals are the principal interest because of the
frequent and extended use of antimicrobials. In
order to use antibiotics properly the first step is to
calculate the amount of antimicrobials that has
been used. The second step is to compare data in
order to recognize problems and then to improve
antimicrobial use. Here we used US-AUR and INICC
data as a benchmarking instrument. We chose these
data for various reasons. Firstly, they used the same
antimicrobial groups; secondly, US-AUR data have
the advantage of having data from all types of ICUs;
finally, INICC represents multinational data. But
they have some disadvantages too. For example, the
NNIS system report does not contain antimicrobial
use data since 2004 and their antimicrobial group
selection was not properly equal to WHO ATC
group and some antimicrobials are not available in
the market in Turkey (for example antistaphylococcal
penicillins). Although INICC data are multinational
most of the participating hospitals are from Latin
America, which may or may not resemble our
hospital. For most antimicrobial group the AD was
over the 90th percentile according to US-AUR data
but it is in the normal range according to INICC
data (2,3). Especially antipseudomonal penicillin
(piperacillin, mostly as piperacillin tazobactam) and
carbapenems ADs were higher than US hospitals.
We have noted both higher device utilization ratios
and higher device associated infections than those
reported by the NNIS system (data are shown
in Table 5 but are not compared). Antimicrobial
use must be reevaluated together with the rate of
nosocomial infections and resistant microorganisms.
In contrast to these antimicrobials quinolone use
density was lower in our institution compared with
US-AUR and INICC data in ICUs (2,3). This may
be in part due to the fact that quinolones are mostly
used in outpatients or non-ICU departments and the
usage of intravenous forms are under the control of
infectious disease specialist according to the health
practice rescript in Turkey.

In ICU and non-ICU departments as well the
ampicillin group had the highest AD, followed by
1st generation cephalosporins. When compared
with INICC the use of 1st generation cephalosporins
was in the 75th-90th and >90th percentile, for ICU
and non-ICU departments respectively. Although
a recent consensus statement from the National
Surgical Infection Prevention Project recommended
surgical prophylaxis not to be extended beyond 24 h
in most cases, in our institution in most cases surgical
prophylaxis extended beyond 24 h (13). After this
result we decided to implement an education program
and prepared a surgical prophylaxis guideline.
Incidence densities of all nosocomial infections
and ventilator utilization rates were correlated at
ICUs with the use of antipseudomonal penicillins,
3rd generation cephalosporins, carbapenems,
and glycopeptides. These are broad spectrum
antimicrobials and probably were used to treat
nosocomial infections, which are likely to be more
resistant pathogens. This may explain the correlation
with the incidence densities of nosocomial infections.
It is difficult to explain the correlation with the
ventilator utilization rate. One can speculate that the
high utilization rate is likely to result in high ventilator
associated pneumonia rate, which is highly mortal,
which in turn is likely to result in a high empirical use
of broad spectrum antibiotics.
Since 1993, the institutional policies of hospital
infection control have been implemented by an
infection control team (14). Until 2006 antibiotic
policies were decided and implemented by that team in
collaboration with the infectious disease department.
In 2006 an antimicrobial control subcommittee was
created. The implementation of nosocomial infection
surveillance has gained widespread acceptance in
Turkey and there is a national program for monitoring
nosocomial infections but there is no national
program for monitoring antimicrobial use. It may
be more practical to have national comparative data
for antimicrobial use. Some countries in Europe, for
example Sweden and Germany, improve their national
project on antimicrobial use in ICUs. The Swedish
STRAMA project (ICU section of the Swedish Strategic
Program for the Rational Use of Antimicrobial Agents
and Surveillance of Resistance) and the German
SARI Project (Surveillance of Antimicrobial Use and
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Antimicrobial Resistance in Intensive Care Units) are
government sponsored. The main objective of these 2
surveillance systems is to provide information on the
use of antimicrobials in risk areas such as ICUs, and to
supply data on the incidence percentages of resistant
bacterial pathogens and to serve as a benchmark for
hospitals in their countries (15,16).

program for antimicrobial usage may provide more
precise data for inter-hospital comparisons.

In conclusion, this is the first report on
antimicrobial consumption from a Turkish university
hospital separately. The main finding of our study
was a positive correlation between nosocomial
infections densities and the use of broad spectrum
antimicrobials. Moreover, a high AD for 1st generation
cephalosporins was noted in ICU and non-ICU
departments. To use antimicrobials wisely we must
implement a comprehensive education program
together with infection control measures. A national
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